Friday, December 5, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Immersion Faces Nasdaq Compliance Challenge Over Delayed Filing

Andreas Sommer by Andreas Sommer
September 4, 2025
in Earnings, Nasdaq, Tech & Software
0
Immersion Stock
0
SHARES
198
VIEWS
Share on FacebookShare on Twitter

Shares of Immersion Corporation came under scrutiny after the haptics technology specialist received a formal notification from the Nasdaq stock market regarding a compliance issue. The alert, issued on August 20, 2025, stems from the company’s failure to timely file its Annual Report on Form 10-K for the fiscal year that concluded on April 30, 2025.

The delay is directly connected to an ongoing internal investigation being conducted by the audit committee of Barnes & Noble Education (BNED), a subsidiary of Immersion. This development has introduced significant uncertainty for investors, prompting heightened attention to the company’s regulatory compliance efforts.

Key Details of the Notification:
* Notification Date: August 20, 2025
* Nature of Breach: Late submission of the Form 10-K annual report
* Root Cause: Internal probe at subsidiary Barnes & Noble Education (BNED)
* Response Deadline: 60 calendar days to submit a plan to regain compliance

Should investors sell immediately? Or is it worth buying Immersion?

In response to the notification, Immersion now has a 60-day window to present a detailed plan to Nasdaq outlining its path to rectifying this filing delinquency. A failure to satisfy the exchange’s requirements could lead to further disciplinary actions, including the potential for the stock’s delisting.

Reflecting the cautious market sentiment, Immersion’s stock closed its latest session at $7.01. The immediate focus for the company is squarely on resolving the filing delay and navigating the complexities of the internal investigation at BNED.

Despite these recent regulatory headwinds, some market analysts maintain a measured outlook on the stock’s potential. The current average price target among covering analysts stands at $12.25. This figure suggests a substantial upside potential of over 75% from the recent closing price of $6.99. While the average broker recommendation has softened from 1.50 to 2.00, it continues to signal an overall positive assessment of the company’s long-term value.

Ad

Immersion Stock: Buy or Sell?! New Immersion Analysis from December 5 delivers the answer:

The latest Immersion figures speak for themselves: Urgent action needed for Immersion investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 5.

Immersion: Buy or sell? Read more here...

Tags: Immersion
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Shares Remain Under Pressure as Regulatory Concerns Linger

December 5, 2025
Procter & Gamble Stock
Consumer & Luxury

P&G Shares Under Pressure as Finance Chief Highlights U.S. Demand Weakness

December 5, 2025
Healwell AI Stock
AI & Quantum Computing

Healwell AI Shares Show Tentative Signs of Finding a Floor

December 5, 2025
Next Post
G1 Therapeutics Stock

G1 Therapeutics Acquisition Finalized in Landmark $405M Deal

Monopar Therapeutics Stock

Monopar Therapeutics Stock Surges on Clinical Progress and Analyst Optimism

Voyager Therapeutics Stock

Voyager Therapeutics Stock Gains Momentum Following Investor Conference Appearances

Recommended

Standard Lithium Stock

Standard Lithium Reaches Critical Milestone in Arkansas Venture

1 month ago
BioNTech Stock

BioNTech Shares Plunge as Financial Performance Raises Concerns

2 months ago
Fannie Mae Stock

Fannie Mae Shares Face Intensifying Pressure Amid Leadership Overhaul

4 weeks ago
Canaan Stock

Canaan Shares Face Critical Test Amid Expansion Moves

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Setback for European Lithium as Key Austrian Permit Overturned

ServiceNow Pursues Dual-Pronged Strategy with Major Acquisition and Stock Split

Institutional Investors Drive Significant Accumulation in ADT Shares

AvePoint’s Robust Performance and Strategic Edge in AI Governance

Coeur Mining Stock Faces Conflicting Market Pressures

CureVac Nears Final Chapter with BioNTech Acquisition and Index Removal

Trending

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Shares Remain Under Pressure as Regulatory Concerns Linger

by Andreas Sommer
December 5, 2025
0

Shares of genome-editing company Intellia Therapeutics closed the trading week in negative territory, continuing a period of...

Procter & Gamble Stock

P&G Shares Under Pressure as Finance Chief Highlights U.S. Demand Weakness

December 5, 2025
Healwell AI Stock

Healwell AI Shares Show Tentative Signs of Finding a Floor

December 5, 2025
European Lithium Stock

Setback for European Lithium as Key Austrian Permit Overturned

December 5, 2025
ServiceNow Stock

ServiceNow Pursues Dual-Pronged Strategy with Major Acquisition and Stock Split

December 5, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Intellia Therapeutics Shares Remain Under Pressure as Regulatory Concerns Linger
  • P&G Shares Under Pressure as Finance Chief Highlights U.S. Demand Weakness
  • Healwell AI Shares Show Tentative Signs of Finding a Floor

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com